Clinical trials: Urinary System Disorder
End Stage Renal Disease (ESRD)
HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis
The main objective of this research study was to compare the following outcomes between patients with a Hemodialysis Reliable Outflow (HeRO) Graft and patients with a cuffed catheter for dialysis access over one year: quality of…
- Trial name
- NCT01343251
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merit Medical Systems, Inc.
Renal Failure, Hemodialysis
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the…
- Trial name
- REVISE (NCT00737672)
- Testing
- GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, Percutaneous Transluminal Angioplasty
- Where
- 31 sites in United States
- Volunteers
- 293 people
- Sponsor
- W.L.Gore & Associates
Kidney Diseases, Chronic Renal Insufficiency
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States.
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Trial name
- NCT00268957
- Testing
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Where
- 29 sites in United States
- Volunteers
- 217 people
- Sponsor
- Genzyme, a Sanofi Company
Urinary Incontinence, Fecal Incontinence
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)
This clinical investigation is a single-arm, prospective, multicentre, early feasibility study, which is used to evaluate the device design of UCon with respect to initial clinical safety and device performance in a small number…
- Conditions
- Urinary Incontinence, Fecal Incontinence, Urge Incontinence, Nocturia
- Trial name
- NCT05368246
- Testing
- UCon
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- InnoCon Medical
Chronic Kidney Disease
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
The purpose of the study was to evaluate the efficacy and safety of HS-10390 in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 30 and <90 mL/min/1.73 m^2, and urinary albumin to…
- Trial name
- NCT07555054
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Bladder Cancer Transitional Cell Carcinoma
Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
This study includes two semi-consecutive parts: Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.
- Trial name
- NCT01551342
- Where
- 7 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Zetiq Technologies
Kidney Disease
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment
The purpose of this study is to characterize the safety and tolerability of single doses of compound 1278863A in subjects with renal impairment.
- Trial name
- NCT00935831
- Testing
- GSK1278863A
- Where
- New Zealand
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease, Hemodialysis Patients
Association Between Dose Dialysis by Kt and Mortality
The aim of this study is to assess whether patients receiving current recommendations of an adequate dialysis dose by Kt adjusted for body surface area improved survival at 24 months compared to those who do not get it, as well…
- Trial name
- NCT01932853
- Where
- Spain
- Volunteers
- 6,129 people
- Sponsor
- NephroCare Spain
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Renal Insufficiency
Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects
This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.
- Trial name
- NCT01660295
- Testing
- Certoparin 3,000 IU Once Daily, Certoparin 3,000 IU Twice a Day, Certoparin 8,000 IU Once Daily
- Where
- Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Neuflo System for the Treatment of BPH
The goal of this clinical study is to assess the effectiveness and safety of the Neuflo System for the treatment of benign prostatic hyperplasia (BPH).
- Trial name
- NCT05884580
- Testing
- Neuflo BPH Treatment System
- Where
- New Zealand
- Volunteers
- 1 people
- Sponsor
- ProstaCare Pty Ltd
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
- Trial name
- NCT00509262
- Testing
- Sitagliptin, Glipizide
- Volunteers
- 426 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis
- Trial name
- NCT01464931
- Testing
- Denosumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Amgen
Kidney Failure, Chronic
Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate
- Trial name
- NCT00151931
- Testing
- Lanthanum carbonate
- Volunteers
- 456 people
- Sponsor
- Shire
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
Glomerulosclerosis, Focal Segmental
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT04340362
- Testing
- VX-147
- Where
- 44 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Anemia, Renal Insufficiency, Chronic
15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood.
- Trial name
- DIALOGUE 1 (NCT02021370)
- Testing
- BAY85-3934
- Where
- 56 sites in Australia, Bulgaria and 12 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
- Trial name
- NEXST (NCT01557127)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Poland
- Volunteers
- 205 people
- Sponsor
- Bayer
Cystitis, Interstitial
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary…
- Trial name
- NCT00999518
- Testing
- Tanezumab
- Where
- 171 sites in United States, Belgium and 12 more
- Volunteers
- 205 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.